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This article presents detailed puriﬁcation procedures for the bro-
modomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B. In addition
we provide crystallization protocols for apo BRD4(1) and BRD4
(1) in complex with numerous inhibitors. The protocols described
here were successfully applied to obtain afﬁnity data by isothermal
titration calorimetry (ITC) and by differential scanning ﬂuorimetry
(DSF) as well as structural characterizations of BRD4(1) inhibitor
complexes (PDB codes: PDB: 4LYI, PDB: 4LZS, PDB: 4LYW, PDB:
4LZR, PDB: 4LYS, PDB: 5D24, PDB: 5D25, PDB: 5D26, PDB: 5D3H,
PDB: 5D3J, PDB: 5D3L, PDB: 5D3N, PDB: 5D3P, PDB: 5D3R, PDB:vier Inc. This is an open access article under the CC BY license
burg.de (D. Wohlwend).
44, CH-4416 Bubendorf.
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Fig. 1. Puriﬁcation chromatogram of His6-BRD4(1)
blue curve represents the concentration of imidazo
with a black arrow, molecular weights of the mark
the framed peak.5D3S, PDB: 5D3T). These data have been reported previously and
are discussed in more detail elsewhere [1,2].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ubject area Chemistry, Biology
ore speciﬁc sub-
ject areaStructural biology, drug discoveryype of data Table, chromatograms, crystal images
ow data was
acquiredChromatograms were acquired on Äkta Prime Plus systems, crystal images
were acquired with a Zeiss SteREO Discovery 2.0 microscope equipped with a
Canon EOS 600D CCD cameraata format Processed
xperimental
factorsAll proteins were produced heterologously in E. coli.xperimental
featuresProteins were isolated by IMAC via His6-tag followed by tag cleavage with
TEV and polishing via size exclusion chromatography. Proteins were con-
centrated for crystallization to 10 mg/mL and supplied with ligands at a
concentration of 2 mM.ata source
locationInstitut für Biochemie, Albert-Ludwigs-Universität Freiburg, Albertstraße 21,
D-79104 Freiburg, Germanyata accessibility Data is within this article. Structures were deposited in the PDB with the
following PDB codes: PDB: 4LYI, PDB: 4LZS, PDB: 4LYW, PDB: 4LZR, PDB:
4LYS, PDB: 5D24, PDB: 5D25, PDB: 5D26, PDB: 5D3H, PDB: 5D3J, PDB: 5D3L,
PDB: 5D3N, PDB: 5D3P, PDB: 5D3R, PDB: 5D3S, PDB: 5D3Tvia Ni-IMAC. The red curve shows the absorption at 280 nm in mAU, the
le. (SDS-Gel) SDS-Gel of the framed peak. Bands of His6-BRD4(1) are marked
er are as indicated and the F-numbers above the gel refer to the fractions of
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 Provides details on puriﬁcation and crystallization of BRD4(1).
 Provides details on co-crystallization strategies of BRD4(1) with inhibitors.
 Provides details on puriﬁcation of BRD3(1), BRD3(2), and BRPF1B.
 Data shown here may serve as benchmarks for other groups working with bromodomains.1. Data
We present a detailed strategy for the heterologous overproduction and puriﬁcation of BRD4
(1) including chromatograms and SDS-gels, shown in Figs. 1 and 2. The data allowed for the char-
acterization of 25 inhibitors for bromodomains with a special focus on BRD4(1), published in [1] and
[2]. The protocol shown here was also used for the preparation of BRPF1B, BRD3(1) and BRD3(2) to
determine their afﬁnities to various novel inhibitors (see [1] for original afﬁnity data). In addition, we
provide photographs of crystals of apo BRD4(1) (Fig. 4) and BRD4(1) in complex with several inhi-
bitors (Fig. 3).
For 14 inhibitors we obtained high resolution X-ray structures in complex with BRD4(1) [1,2].
Structure formulas, SMILES strings and pdb ID codes are summarized in Supplementary Table 1.2. Experimental design, materials and methods
2.1. Protein preparation
The plasmids for protein production are gifts from Nicola Burgess-Brown, purchasable via Addgene
(Addgene plasmids # 38941, # 53620, # 38940, # 38943). All constructs share the vector backbone
pNIC28-Bsa4 with a Kanamycin resistance gene. They encode for an N-terminal His6-tag followed by a
TEV-cleavage site N-terminal of the target protein.
Chemically competent BL21 (DE3) cells were transformed with the constructs and plated on LB-
Agar plates with Kanamycin (50 mg/ml). Single colonies were picked for preparatory cultures (LB
media, 50 mg/ml Kanamycin, 37 °C, overnight). The preparatory cultures (10 ml) were then used to
inoculate TB media (1 L, 50 mg/ml Kanamycin, 37 °C). At an OD600¼2.5 the cells were cooled down to
20 °C and at an OD600¼3 induced with IPTG (0.1 mM). Cells were harvested by centrifugationFig. 2. Puriﬁcation chromatogram of BRD4(1) via size exclusion column. The red curve shows the absorption at 280 nm in
mAU. (SDS-Gel) SDS-Gel of the framed peak. Bands of BRD4(1) are marked with a black arrow, molecular weights of the marker
are as indicated and the F-numbers above the gel correspond to the fractions of the framed peak.
Fig. 4. Spontaneous BRD4(1) crystal formation in reaction tube. BRD4(1) (20 mg/mL in crystallization buffer) crystals grown in
a 1.5 ml reaction tube at 12 °C after two weeks.
Fig. 3. BRD4(1) crystals with various ligands. Initial drop size was always 400 nL. Crystal shapes differed only slightly evenwith
different ligands and crystallization conditions. All crystals shared the space group P21 21 21 yet with differing cell axes.
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were re-suspended in lysis buffer (3 ml per g cells, 50 mM HEPES/NaOH, pH 7.5 at 20 °C, 500 mM
NaCl, 30 mM Imidazole) and lysed using a M-110P ﬂuidizer (Microﬂuidics, UK). Each lysate was
cleared by centrifugation (100,000xg, 45 min, 4 °C, JA-30.50Ti rotor, Beckman Coulter Avanti J-30I)
followed by ﬁltration (0.45 mm). The ﬁltered supernatant was then loaded onto a Nickel afﬁnity
column (5 ml HisTrap, GE Healthcare, Germany, equilibrated with 20 ml lysis buffer) connected to an
ÄKTAPrime plus system (GE Healthcare, Germany). Immobilized protein was washed with lysis buffer
to baseline and eluted in a linear gradient of imidazole in lysis buffer (0 to 250 mM imidazole over
100 ml, Fig. 1). The eluate was fractionated and analyzed via SDS-PAGE. The eluted target proteins
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lyzed via SDS-PAGE, and further puriﬁed via size exclusion chromatography (HiLoad Superdex 75 XK
26/60, GE Healthcare, Germany, equilibrated with 400 ml crystallization buffer, 10 mM HEPES/NaOH,
pH 7.5 at 20 °C, 150 mM NaCl) on an ÄktaPrime plus system (Fig. 2). Eluted proteins were analyzed via
SDS-PAGE and concentrated to 10 mg/ml (VIVASPIN TURBO 15, 10,000 MWCO, Sartorius, Germany).
2.2. Protein crystallization
Prior to crystallization the protein solutions were supplemented with inhibitor from a 100 mM
stock solution in DMSO to a ﬁnal inhibitor concentration of 2 mM Subsequently, precipitated protein
was removed by centrifugation (16,000xg, 4 °C, 5 min, Centrifuge 5415 R, Eppendorf, Germany). Co-
crystals with the described inhibitors were obtained in the Index HT Screen (Hampton Research, Aliso
Viejo, USA) using 38% protein (10 mg/ml) and 62% reservoir solution. The drops (400 nl) were
pipetted into an Intelli-Plate 96 low proﬁle (Hampton Research, USA) with an Oryx Nano crystal-
lization robot (Douglas Instruments, UK). Single crystals formed after one to ﬁve days at 20 °C (Fig. 3).
Note, that BRD4(1) crystallizes spontaneously after two weeks in the ﬁnal crystallization buffer at 10–
12 °C in a reaction tube, if the concentration exceeds 20 mg/ml (Fig. 4).Acknowledgments
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